MediWound to Report Fourth Quarter and Year-End 2022 Financial Results
Conference Call and Webcast Scheduled for Thursday, March 16 at 8:30 am Eastern TimeYAVNE, Israel, March 02, 2023 (GLOBE NEWSWIRE)...
Clinical Trial
PharmAla Biotech named Exclusive MDMA Supply Partner to Awakn Life Sciences
PharmAla will be the sole provider of both GMP and Engineering MDMA to AwaknVANCOUVER, British Columbia, March 02, 2023 (GLOBE...
Biomea Fusion To Participate In Upcoming Investor Events
REDWOOD CITY, Calif., March 02, 2023 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a biopharmaceutical company focused on...
Avenue Therapeutics Enters into a Transformational License Agreement with AnnJi Pharmaceutical to Develop and Commercialize AJ201, a First-in-Class Clinical Asset for the Treatment of Spinal and Bulbar Muscular Atrophy
AJ201 is being evaluated in a Phase 1b/2a clinical trial in the U.S. for the rare X-linked genetic neurodegenerative disease...
Algernon NeuroScience Appoints Global TBI Expert and Former NFL Neurological Player Care Safety Director Dr. David Brody to Advisory Board
VANCOUVER, British Columbia, March 02, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or...
Aerovate Therapeutics to Present at Cowen 43rd Annual Health Care Conference
WALTHAM, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on...
Microbot Medical Meeting with Key Opinion Leaders, Hospital Administrators, and Potential Strategic and Commercial Partners at the Society of Interventional Radiologist Annual Meeting
Continues to Raise Awareness of the LIBERTY® Robotic System Ahead of Commercialization PlansHINGHAM, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) --...
Parexel Introduces Expert Series – New Medicines, Novel Insights
New evidence-based reports offer timely analysis and actionable guidance to drug developers bringing critical new therapies to marketDURHAM, N.C., Feb. 28,...
AIM ImmunoTech Announces Phase 2 Study of Ampligen® for the Treatment of Pancreatic Cancer is Open and Recruiting Patients
Ongoing efforts to open additional clinical sites for recruitment at premier cancer centers across the U.S. and Europe are in...
ABVC BioPharma Provides 2023 Pipeline Update
FREMONT, CA, Feb. 28, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical...
Longeveron Appoints Wa’el Hashad as Chief Executive Officer
Hashad is a former executive at Avanir, Amgen, Boehringer Ingelheim, Eli Lilly, and early-stage biotechnology companies Global leader brings over...
ContraFect Announces Pricing of $10.0 Million Registered Direct Offering and Concurrent Private Placement
YONKERS, N.Y., Feb. 28, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery...
Scilex Holding Company announces the commercial launch of ELYXYBTM (celecoxib oral solution) in the U.S., strengthening its leadership position in non-opioid pain management
ELYXYBTM is a first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or...
Sirona Biochem Receives Antiviral Testing Results
VANCOUVER, British Columbia, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) is...
Exagen Inc. to Participate in Upcoming March Conferences
SAN DIEGO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that...
Adial Pharmaceuticals Announces Closing of $0.75 Million At-The-Market Registered Direct Offering
CHARLOTTESVILLE, Va., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage...
Microbot Medical Expands its Geographic Presence to South America with the Addition of Francisco C. Carnevale, MD, PhD, FSIR to its Scientific Advisory Board
Increases Key Opinion Leaders to 13 Throughout the Americas, Israel, and Europe to Support the Company’s Next Regulatory and Commercialization...
Nexcella Announces 50 Patients Already Treated with CAR-T NXC-201; Estimates 100-Patient Total Enrollment for U.S. Food and Drug Administration Approval BLA Submission
Robust enrollment of up to 5 patients per month continues in ongoing Phase 1b/2a next-generation CAR-T NXC-201 clinical trial in...
Altamira Therapeutics Files Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment
HAMILTON, BERMUDA, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Altamira’s ability to target different KRAS mutations with a single polyvalent siRNA...
Nexcella Announces 50 Patients Already Treated with CAR-T NXC-201; Estimates 100-Patient Total Enrollment for U.S. Food and Drug Administration Approval BLA Submission
Robust enrollment of up to 5 patients per month continues in ongoing Phase 1b/2a next-generation CAR-T NXC-201 clinical trial in...